Abstract
OBJECTIVE: To explore and compare the value of (131)I-TFMP-Y4 and (131)I-Caerin 1.1 in internal irradiation therapy for hepatocellular carcinoma. METHODS: (1) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis revealed the inhibitory effects of Caerin 1.1 and TFMP-Y4 on Hepg2 and LO2 cell growth. (2) The chloramine-T method was used to prepare (131)I-Caerin 1.1 and (131)I-TFMP-Y4. (3) Uptake and elution assays revealed that Hepg2 cells bound and retained (131)I-Caerin 1.1 and (131)I-TFMP-Y4, and the inhibitory effects on Hepg2 cells were verified with cellular proliferation/toxicity assays. (4) A hormonal nude mouse model was established to study the in vivo therapeutic effects of the peptides alone, (131)I-Caerin 1.1 and (131)I-TFMP-Y4. RESULTS: (1) Caerin 1.1 inhibited Hepg2 and LO2 cell proliferation in a concentration-dependent manner, and the half-maximal inhibitory concentrations (IC(50)) were 9.34 µg/mL and 22.16 µg/mL, respectively. Moreover, TFMP-Y4 did not inhibit these two cell lines. (2) The labeling rates of (131)I-Caerin 1.1 and (131)I-TFMP-Y4 were high and stable. Both could significantly reduce the activity of Hepg2 cells and inhibit tumor growth in vitro and in vivo. CONCLUSION: (131)I-Caerin 1.1 and (131)I-TFMP-Y4 significantly inhibited the proliferation of Hepg2 cells in vitro and in vivo. In addition, (131)I-TFMP-Y4 can reduce adverse reactions during treatment.